Nexavar (Sorafenib)

Sorafenib blocks several key kinases involved in tumor growth and blood‑vessel formation, such as Raf, VEGFR‑2, VEGFR‑3, PDGFR‑β, c‑KIT, FLT‑3 and RET. By inhibiting these enzymes, the drug reduces cancer cell proliferation, limits new blood‑vessel development (angiogenesis), and interferes with signals that promote metastasis.

The specific dose of Nexavar is determined by the treating physician based on the patient’s condition, weight, liver function, and tolerance. Prescribers typically start with a standard regimen and may adjust it according to clinical response and any adverse effects, following local prescribing guidelines.

Sorafenib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is advised for both men and women of reproductive potential. Safety during breastfeeding has not been established, so nursing mothers should avoid the drug.

To request Nexavar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative to sorafenib in many indications is sunitinib, another oral multikinase inhibitor. Both target angiogenic pathways, but sorafenib has a broader kinase profile that includes Raf kinases, while sunitinib focuses more on VEGFR and PDGFR. Clinical choice often depends on efficacy data, side‑effect tolerability, and physician experience.

Nexavar tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct light, and ensure the packaging remains sealed until use. Do not refrigerate or freeze the tablets.

Nexavar is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing and any dietary considerations. Swallow the tablet whole; do not crush or chew it.

The most serious adverse events include severe hypertension, cardiac ischemia or infarction, significant liver toxicity (elevated bilirubin or transaminases), and major bleeding episodes. Patients should be monitored regularly for blood pressure, cardiac symptoms, liver function tests, and any signs of abnormal bleeding.

Nexavar is contraindicated in patients with severe hepatic impairment, uncontrolled hypertension, recent myocardial infarction, or known hypersensitivity to sorafenib or any tablet components. It should also be avoided during pregnancy and is not recommended for breastfeeding mothers. Physicians must assess each patient’s medical history before prescribing.